NCT00153608Unknown2 期
Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Clinical efficacy
研究概览
简要总结
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic cancer, no standard treatment option
- •Resected cancer with minimal residual disease, no standard treatment option
- •WT-1 expression
排除标准
- •Concurrent chemotherapy
结局指标
主要结局
Clinical efficacy
次要结局
- Immune response
- Safety
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaMyelodysplastic SyndromeNCT00153582Charite University, Berlin, Germany25
已完成
2 期
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaNCT01266083Sellas Life Sciences Group22
已完成
不适用
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid NeoplasmsLeukemiaNCT00665002H. Lee Moffitt Cancer Center and Research Institute16
已完成
2 期
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic MalignancyAcute Myeloid Leukemia (AML)Chronic Myeloid Leukemia (CML)Myelodysplastic SyndromeNCT00433745National Heart, Lung, and Blood Institute (NHLBI)4
已完成
1 期
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian CancerFallopian TubePrimary Peritoneal CancerRecurrent Ovarian CancerOvarian CancerNCT02737787Memorial Sloan Kettering Cancer Center11